Ajanta Pharma Limited (NSE: AJANTPHARM)

Ajanta Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	649.3	1,295	3,298	2,064	1,775	2,024
Short-Term Investments	6,770	-	-	-	250	-
Trading Asset Securities	-	3,301	5,103	1,219	1,757	671.4
Cash & Short-Term Investments	7,419	4,595	8,401	3,282	3,782	2,695
Cash Growth	56.00%	-45.30%	155.96%	-13.21%	40.33%	68.54%
Accounts Receivable	10,164	12,468	10,569	10,198	7,384	7,753
Other Receivables	-	696.6	459.2	460.5	862.2	466.6
Receivables	10,366	13,505	11,202	10,722	8,327	8,310
Inventory	8,457	8,284	8,156	7,911	7,665	4,957
Prepaid Expenses	-	259.2	164.4	155.8	138.4	223.6
Other Current Assets	1,706	666.4	416.2	573.6	364.2	232.1
Total Current Assets	27,948	27,309	28,340	22,645	20,276	16,417
Property, Plant & Equipment	17,868	17,210	16,982	16,474	16,296	15,829
Long-Term Investments	248.3	227.4	290	294.2	39.5	159.3
Other Intangible Assets	133.2	146.6	77.5	90.2	107.9	117.1
Long-Term Deferred Tax Assets	1,464	1,345	967.7	555.5	501	254
Other Long-Term Assets	244	146.4	133.4	497.1	566.8	345.2
Total Assets	47,905	46,384	46,790	40,556	37,787	33,187
Accounts Payable	4,209	4,632	4,228	3,272	3,739	3,623
Accrued Expenses	211.7	671.3	356.8	375.9	352.1	258.6
Short-Term Debt	-	15.6	38.4	94.9	63.9	465.1
Current Portion of Long-Term Debt	24.2	-	-	-	-	-
Current Portion of Leases	88.3	117.6	94.3	64.6	115.9	194
Current Income Taxes Payable	552	447.7	330.7	79.4	489.2	117
Current Unearned Revenue	-	3.3	3.3	3.3	3.3	3.3
Other Current Liabilities	4,005	3,070	6,342	2,584	1,723	1,400
Total Current Liabilities	9,090	8,958	11,393	6,474	6,486	6,062
Long-Term Leases	215.4	235.2	262	185.7	197.7	127.1
Long-Term Unearned Revenue	21.7	23.4	26.7	30	33.4	36.7
Long-Term Deferred Tax Liabilities	1,126	1,085	977.2	1,019	921.7	811.6
Other Long-Term Liabilities	682.7	274.1	228.4	204.1	180.9	134.8
Total Liabilities	11,136	10,710	12,910	7,912	7,831	7,198
Common Stock	250.7	251.8	251.8	170.8	173	174.5
Additional Paid-In Capital	-	1.8	-	-	-	10.6
Retained Earnings	-	35,254	33,523	32,495	29,726	25,684
Comprehensive Income & Other	36,519	166.2	105	-22.1	57.7	120
Shareholders' Equity	36,770	35,674	33,880	32,643	29,956	25,989
Total Liabilities & Equity	47,905	46,384	46,790	40,556	37,787	33,187
Total Debt	327.9	368.4	394.7	345.2	377.5	786.2
Net Cash (Debt)	7,091	4,227	8,006	2,937	3,404	1,909
Net Cash Growth	60.23%	-47.20%	172.60%	-13.73%	78.36%	80.66%
Net Cash Per Share	56.41	33.55	62.49	22.65	26.06	14.58
Filing Date Shares Outstanding	125.35	126.68	125.91	128.12	129.8	130.89
Total Common Shares Outstanding	125.35	126.68	125.91	128.12	129.8	130.89
Working Capital	18,858	18,352	16,947	16,171	13,790	10,355
Book Value Per Share	293.33	281.60	269.07	254.78	230.79	198.55
Tangible Book Value	36,636	35,527	33,802	32,553	29,848	25,872
Tangible Book Value Per Share	292.27	280.44	268.45	254.08	229.96	197.66
Land	-	1,488	1,577	1,575	1,556	1,554
Buildings	-	6,174	6,057	5,870	5,677	5,427
Machinery	-	14,692	13,879	13,276	12,614	11,370
Construction In Progress	-	2,565	2,095	1,529	1,082	1,319
Leasehold Improvements	-	-	-	10.9	11.7	11.6

Source: S&P Capital IQ. Standard template. Financial Sources.